New antibody drug shows promise for Hard-to-Treat cancers
Disease control
Ongoing
This study tests a new drug called MCLA-129 in people with advanced lung, stomach, esophageal, head/neck, or colorectal cancers that have not responded to standard treatments. The drug is a bispecific antibody designed to attack two cancer-related targets at once. The goal is to …
Phase: PHASE1, PHASE2 • Sponsor: Merus B.V. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC